Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02989636 · ClinicalTrials.gov registry record · Phase 1
Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma
A Phase 1 study of Chordoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Active
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
- 2
- Study locations
NCT02989636: Active Phase 1 study of Chordoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT02989636 is a Phase 1 study of Chordoma that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 21 participants, below the 86-participant average among 15 other Chordoma trials with a reported enrollment target (76% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02989636, a Phase 1 study of Chordoma, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase I trial studies the side effects of nivolumab with or without stereotactic radiosurgery (SRS) in treating patients with chordoma that has come back or spread from where it started to other places in the body. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. It is not yet known whether giving nivolumab with or without stereotactic radiosurgery may work better in treating patients with chordoma.
Primary Outcome
Proportion of serious adverse events will be estimated using the binomial distribution along with 95% confidence interval (exact method).
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Nivolumab
- RADIATION Stereotactic Radiosurgery
Study Locations (2)
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-03-10 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What the registry record for NCT02989636 still lists
NCT02989636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 86-participant average among 15 other Chordoma trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Chordoma appearing as the primary indexed condition, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02989636 reports a single indexed study location in Maryland, New York.
Frequently Asked Questions
What is clinical trial NCT02989636 about?
NCT02989636 is a clinical study titled "Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma". This phase I trial studies the side effects of nivolumab with or without stereotactic radiosurgery (SRS) in treating patients with chordoma that has come back or spread from where it started to other places in the body. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumo...
What is the current status of trial NCT02989636?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-03-10. Estimated completion is 2026-11.
What conditions does trial NCT02989636 study?
This clinical trial studies the following conditions: Chordoma.
What interventions are being tested in trial NCT02989636?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Nivolumab (BIOLOGICAL), Stereotactic Radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT02989636?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02989636 being conducted?
This trial has 2 study locations across Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chordoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02989636's enrollment target sits among peer trials
21 13th of 15 higher than 2 of 15 other Chordoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chordoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
RECRUITING · Phase 1
-
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
RECRUITING · Phase 1
-
A Study of ERAS-601 in People With Chordoma
RECRUITING · Phase 1
-
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
COMPLETED · Phase 1
-
Nilotinib With Radiation for High Risk Chordoma
COMPLETED · Phase 1
-
Children and Adults With Chordoma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI